SPN and leukemia: Siglec-7 mediates immune inhibition by interacting with the mucin-type glycoprotein CD43 on leukemia cells, and CD43 knockout or blockade in leukemia cells disrupted this interaction to enhance anti-tumor immune reaction [9].